Ecstasy (MDMA) for social anxiety in autism: a specialized application of empathogen therapy
Annals of Medicine and Surgery April 6, 2026 Mahnoor Sheikh, Zaibunnisa Bilal, Syeda Habiba Fatima et al.
Autistic adults often experience social anxiety that persists despite behavioral interventions. A randomized, double-blind, placebo-controlled pilot trial found that MDMA-assisted psychotherapy significantly reduced social fear and anxiety in autistic adults. MDMA appears to enhance prosocial behaviors and empathy, partly by reducing amygdala reactivity and releasing oxytocin. Common acute side effects include fatigue, reduced appetite, jaw clenching, and sweating; cardiovascular effects such as transient hypertension and tachycardia occur, contraindicating use in patients with heart conditions. Delayed effects can include transient anxiety and depressed mood. The therapy was well-tolerated under controlled clinical settings, but small sample sizes and lack of long-term follow-up limit conclusions. Larger trials are needed before MDMA can be considered for autism-related therapies.